Incyte Corporation (INCY) Stock Analysis
Last updated Sep 8, 2026
Published Opportunity
This stock was published as a Compound Radar opportunity on Aug 10, 2026. Performance is tracked publicly from the original signal.
Health Check
Last analyzed Sep 7, 2026
- Financial Health 85
- Profitability 95
- Business Quality 75
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 82/100 — Elite Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Incyte Corporation (INCY) is a Biotechnology company in the Healthcare sector. Compound Radar rates Incyte Corporation 82/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 15.85
- Forward P/E 14
- EV/Revenue 3.64
Profitability
- Revenue Growth 37.7%
- Gross Margin 55.7%
- Operating Margin 41.9%
- Net Margin 27.7%
- ROE 30.7%
Financial strength
- Cash $4.54B
- Debt $38.27M
- Net Cash $4.50B
- Free Cash Flow $1.33B
- Current Ratio 4.59
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$16.07 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$260.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$108.31 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$528.90 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$42.07 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- ACADIA Pharmaceuticals Inc. Biotechnology ACAD$27.58 75 Health 75 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- BioMarin Pharmaceutical Inc. Biotechnology BMRN$64.63 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Incyte Corporation (INCY).